Literature case analysis of drug-induced liver injury induced by GLP-1 receptor agonists

ZHANG Menghua; ZHU Ying; WU Ziyang; WANG Yanhua; XIONG Xiangzun; MIAO Liyan

doi:10.6039/j.issn.1001-0408.2025.20.13

您当前的位置：

首页 >

文章列表页 >

Literature case analysis of drug-induced liver injury induced by GLP-1 receptor agonists

更新时间：2025-10-25

- Literature case analysis of drug-induced liver injury induced by GLP-1 receptor agonists
- ZHONGGUO YAOFANG Vol. 36, Issue 20, Pages: 2561-2565(2025)
- 作者机构：
  
  1.苏州大学附属第一医院药学部，江苏苏州;215006
  2.昆明医科大学附属第二医院药学部，昆明　650101
  3.重庆大学附属中心医院（重庆市急救医疗中心）药学部，重庆　400010
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2025.20.13
  CLC： R969.3
- Received：06 May 2025，
  
  Revised：2025-09-15，
  
  Accepted：15 September 2025，
  
  Published：30 October 2025
- 稿件说明：
移动端阅览
张梦华,朱颖,吴紫阳,等.GLP-1受体激动剂致药物性肝损伤的文献病例分析 [J].中国药房,2025,36(20):2561-2565.

ZHANG Menghua,ZHU Ying,WU Ziyang,et al.Literature case analysis of drug-induced liver injury induced by GLP-1 receptor agonists[J].ZHONGGUO YAOFANG,2025,36(20):2561-2565.
张梦华,朱颖,吴紫阳,等.GLP-1受体激动剂致药物性肝损伤的文献病例分析 [J].中国药房,2025,36(20):2561-2565. DOI： 10.6039/j.issn.1001-0408.2025.20.13.

ZHANG Menghua,ZHU Ying,WU Ziyang,et al.Literature case analysis of drug-induced liver injury induced by GLP-1 receptor agonists[J].ZHONGGUO YAOFANG,2025,36(20):2561-2565. DOI： 10.6039/j.issn.1001-0408.2025.20.13.

摘要

目的

探讨胰高血糖素样肽-1受体激动剂（GLP-1RAs）致药物性肝损伤（DILI）的临床特征，为临床安全用药提供参考。

方法

以“GLP-1”“GLP-1RAs”“司美格鲁肽”“药物性肝损伤”等为检索词，检索PubMed、Embase、the Cochrane Library、中国知网、万方数据和维普网，收集GLP-1RAs致DILI的相关文献并进行描述性分析。

结果

共纳入11篇文献，共计11例患者。11例患者中，男性4例（36.4%）、女性7例（63.6%）；患者年龄为17～64岁，其中50～65岁患者5例（45.5%）；6例用于治疗糖尿病，5例用于减重；10例患者伴有基础疾病；DILI发生时间最短的为用药后5 d，最长约180 d；GLP-1RAs致DILI以肝细胞损伤型为主（6例），严重程度包括重度（3例）、中度（6例）、轻度（2例），临床表现包括消化道症状、黄疸等；10例患者的DILI与GLP-1RAs的关联性为“很可能”，1例为“可能”；11例患者均经停药及（或）对症治疗后好转。

结论

GLP-1RAs致DILI相对集中于50～65岁人群，以女性为主，合并基础疾病的患者发生风险增加。临床应加强高危人群识别、用药教育（尤其是症状识别）等药学监护；出现相关症状时应立即停药，必要时给予保肝治疗，以保障患者的用药安全。

Abstract

OBJECTIVE

To investigate the clinical characteristics of drug-induced liver injury （DILI） induced by glucagon-like peptide-1 receptor agonists （GLP-1RAs）， and to provide a reference for safe clinical medication.

METHODS

Using search terms such as “GLP-1”“GLP-1RAs”“semaglutide” “drug-induced liver injury”， relevant studies from PubMed， Embase， the Cochrane Library， CNKI， Wanfang Data and VIP were retrieved. Descriptive analysis was performed on cases of DILI induced by GLP-1RAs.

RESULTS

A total of 11 studies， comprising 11 patients， were included. Among them， 4 were male （36.4%） and 7 were female （63.6%）. Patient ages ranged from 17 to 64 years； 5 patients （45.5%） were between 50 and 65 years old. Six patients were treated for diabetes， and five for weight loss. Ten patients had underlying diseases. The shortest time to the onset of DILI was 5 days after medication， while the longest was approximately 180 days. The DILIs induced by GLP-1RAs were mainly hepatocellular injury type （6 cases）； severity levels included severe （3 cases）， moderate （6 cases）， and mild （2 cases）. Gastrointestinal symptoms and jaundice were the most common clinical manifestations. The association between DILI and GLP-1RAs was assessed as “probable” in 10 cases and “possible” in 1 case. All 11 patients improved after drug discontinuation and （or） corresponding treatment.

CONCLUSIONS

DILI induced by GLP-1RAs is relatively concentrated in patients aged 50-65， with a higher incidence in females. The risk may be further increased in patients with underlying diseases. Clinical use of these agents should enhance pharmaceutical care， including identification of high-risk populations and patient education （especially symptom recognition）. When relevant symptoms appear， the drug should be discontinued immediately， with liver-protective therapy initiated when necessary， to ensure patient safety of drug use.

关键词

Keywords

references

DRUCKER D J . Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity [J ] . Diabetes Care ， 2024 ， 47 （ 11 ）： 1873 - 1888 .

SHETTY R ， BASHEER F T ， POOJARI P G ， et al . Adverse drug reactions of GLP-1 agonists：a systematic review of case reports [J ] . Diabetes Metab Syndr ， 2022 ， 16 （ 3 ）： 102427 .

殷欢莉，于磊，苏兰，等 . 司美格鲁肽注射液致重度肝损伤 [J ] . 药物不良反应杂志， 2023 ， 25 （ 12 ）： 763 - 765 .

BJÖRNSSON H K ， BJÖRNSSON E S . Drug-induced liver injury：pathogenesis，epidemiology，clinical features，and practical management [J ] . Eur J Intern Med ， 2022 ， 97 ： 26 - 31 .

MAO Y M ， MA S W ， LIU C H ， et al . Chinese guideline for the diagnosis and treatment of drug-induced liver injury：an update [J ] . Hepatol Int ， 2024 ， 18 （ 2 ）： 384 - 419 .

DANAN G ， TESCHKE R . RUCAM in drug and herb induced liver injury：the update [J ] . Int J Mol Sci ， 2015 ， 17 （ 1 ）： 14 .

MA J Y ， MATHUR K ， MULDOON J L ， et al . Progressive cholestasis and biliary cirrhosis after initiating oral sema-glutide：report from the drug-induced liver injury network [J ] . ACG Case Rep J ， 2022 ， 9 （ 12 ）： e00922 .

SALEHI A M ， HASANZARRINI M ， SALEHI H ， et al . Liraglutide and liver injury：rare case report with literature review [J ] . Endocr Metab Immune Disord Drug Targets ， 2024 ， 24 （ 6 ）： 725 - 729 .

PARVATANENI S ， RAMACHANDRAN R ， THEN E ， et al . An exceedingly rare case of liraglutide-induced liver injury [J ] . Case Rep Gastrointest Med ， 2021 ， 2021 ： 6306149 .

KOMARGODSKI R ， WITTENBERG A ， BAHAT H ， et al . Acute kidney and liver injury associated with low-dose liraglutide in an obese adolescent patient [J ] . Pediatrics ， 2024 ， 154 （ 1 ）： e2023063719 .

KERN E ， VANWAGNER L B ， YANG G Y ， et al . Liraglutide-induced autoimmune hepatitis [J ] . JAMA Intern Med ， 2014 ， 174 （ 6 ）： 984 - 987 .

MAOR Y ， ERGAZ D ， MALNICK S D H ， et al . Liraglutide-induced hepatotoxicity [J ] . Biomedicines ， 2021 ， 9 （ 2 ）： 106 .

PATEL A V ， JOTWANI P M ， LEE T P . Drug-induced liver injury due to dulaglutide use [J ] . Am J Ther ， 2019 ， 26 （ 5 ）： e620 - e622 .

ABDULLAH I ， EL-GHOUSAIN H ， ALENEZI M . Tirzepatide-related acute liver injury [J ] . Eur J Case Rep Intern Med ， 2024 ， 11 （ 9 ）： 004813 .

SOHAL A ， CASANOVA L ， KOWDLEY K V . A rare case of tirzepatide-induced hepatotoxicity [J ] . ACG Case Rep J ， 2024 ， 11 （ 10 ）： e01484 .

FONTANA R J ， CHOI E K ， KAGANOVE J ， et al . First report of tirzepatide hepatotoxicity with jaundice [J ] . Clin Gastroenterol Hepatol ， 2024 ， 22 （ 12 ）： 2538 - 2539 .

YOO B K ， TRILLER D M ， YOO D J . Exenatide：a new option for the treatment of type 2 diabetes [J ] . Ann Pharmacother ， 2006 ， 40 （ 10 ）： 1777 - 1784 .

MUSKIET M H A ， TONNEIJCK L ， SMITS M M ， et al . GLP-1 and the kidney：from physiology to pharmacology and outcomes in diabetes [J ] . Nat Rev Nephrol ， 2017 ， 13 （ 10 ）： 605 - 628 .

NUFFER W A ， TRUJILLO J M . Liraglutide：a new option for the treatment of obesity [J ] . Pharmacotherapy ， 2015 ， 35 （ 10 ）： 926 - 934 .

HOSACK T ， DAMRY D ， BISWAS S . Drug-induced liver injury：a comprehensive review [J ] . Therap Adv Gastroenterol ， 2023 ， 16 ： 17562848231163410 .

MILANI L ， GALINDO C M ， TURIN DE OLIVEIRA N M ， et al . The GLP-1 analog liraglutide attenuates acute liver injury in mice [J ] . Ann Hepatol ， 2019 ， 18 （ 6 ）： 918 - 928 .

ZHU Y ， XU J ， ZHANG D ， et al . Efficacy and safety of GLP-1 receptor agonists in patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease：a systematic review and meta-analysis [J ] . Front Endocrinol（Lausanne）， 2021 ， 12 ： 769069 .

WANG L J . Designing a dual GLP-1R/GIPR agonist from tirzepatide：comparing residues between tirzepatide，GLP-1，and GIP [J ] . Drug Des Devel Ther ， 2022 ， 16 ： 1547 - 1559 .

CHEN M J ， BORLAK J ， TONG W D . High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury [J ] . Hepatology ， 2013 ， 58 （ 1 ）： 388 - 396 .

FRANCE N L ， SYED Y Y . Tirzepatide：a review in type 2 diabetes [J ] . Drugs ， 2024 ， 84 （ 2 ）： 227 - 238 .

中国医药生物技术协会药物性肝损伤防治技术专业委员会，中华医学会肝病学分会药物性肝病学组 . 中国药物性肝损伤诊治指南：2023年版 [J ] . 胃肠病学， 2023 ， 28 （ 7 ）： 397 - 431 .

ANDRADE R J ， AITHAL G P ， DE BOER Y S ， et al . Nomenclature，diagnosis and management of drug-induced autoimmune-like hepatitis（DI-ALH）：an expert opinion meeting report [J ] . J Hepatol ， 2023 ， 79 （ 3 ）： 853 - 866 .

STRAVITZ R T ， LEE W M . Acute liver failure [J ] . Lancet ， 2019 ， 394 （ 10201 ）： 869 - 881 .

中华医学会，中华医学会杂志社，中华医学会肝病分会药物性肝病学组，等 . 中国药物性肝损伤基层诊疗与管理指南：2024年 [J ] . 中华全科医师杂志， 2024 ， 23 （ 8 ）： 813 - 830 .

LARSEN F S ， SCHMIDT L E ， BERNSMEIER C ， et al . High-volume plasma exchange in patients with acute liver failure：an open randomised controlled trial [J ] . J Hepatol ， 2016 ， 64 （ 1 ）： 69 - 78 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Efficacy and safety of tislelizumab in the treatment of advanced non-small cell lung cancer： a meta-analysis

Advances in the clinical application and safety of bispecific antibodies for cancer therapy

Network meta-analysis of first-line treatment of metastatic colorectal cancer with different chemotherapy combination regimens

Efficacy and safety of ruxolitinib in the treatment of myelofibrosis

Efficacy and safety of luspatercept in the treatment of myelodysplastic syndrome anemia：a single-group rate meta-analysis

Related Author

WANG Yanxue

LIAN Xiaotong

LIANG Ziying

GUO Xinyi

YUAN Qiuyi

WANG Jinni

QIN Yixuan

DING Xiaolian

Related Institution

College of Pharmacy， Guangxi Medical University

Guangxi Key Laboratory of Bioactive Molecules Research and Evaluation

Guangxi Key Laboratory of Bio-targeting Theranostics

Dept. of Clinical Pharmacy， Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province， Affiliated Hangzhou First People’s Hospital， School of Medicine， Westlake University

Dept. of Thoracic Surgery， the First Affiliated Hospital， Zhejiang University School of Medicine

⁰